Growth Clinical Trial
Official title:
Growth and Feeding Tolerance of Infants Consuming a Formula Supplemented With Human Milk Oligosaccharides (HMOs): An Uncontrolled, Open-label, Prospective Study
Human milk oligosaccharides (HMOs) represent the third largest solid component of breast milk. Technology advancements made it possible to supplement infant formulas with HMOs (2'FL, LNnT). Two published RCTs have demonstrated that infant formulas supplemented with 2'FL or 2'FL+LNnT are safe, well-tolerated, support normal grow, and may support healthy GI function and confer immune benefits. The performance of HMOs-supplemented formulas assessed in a real-world setting is complementary to previously conducted RCTs conducted in highly controlled clinical settings. Main objectives will be to monitor the safety & tolerance of HMOs-supplemented formulas in larger and diverse infant populations; to assess the performance of HMOs-supplemented formulas in mixed-fed infants, a population that was not studied in previous RCTs but likely represents a relatively common feeding regimen. Finally, considering the potential health/immune benefits of HMOs, it is also important explore the incidences of illnesses (i.e., respiratory illnesses, GI illnesses, and fever) associated with consuming HMOs-supplemented formulas and compare with breastfed infants data.
Objectives:
The main objective of this study is to document the growth and feeding tolerance of healthy
term infants consuming an infant formula supplemented with HMOs for 8 weeks (56 days), in a
real-world setting.
Main endpoints:
1. Growth documented via monitoring the anthropometric parameters including weight, length,
head circumference, BMI and their corresponding z-scores (i.e., z-scores for
weight-for-age, length-for-age, weight-for-length, head circumference-for-age, and
BMI-for-age) calculated using the 2006 WHO Growth Standards
2. Feeding tolerance assessed via monitoring parent-reported overall GI symptom burden
measured by the Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score
(13-item summary score)
Additional objectives:
To describe the following outcomes in infants fed an infant formula supplemented with HMOs:
1. Formula acceptability
2. Despite there are no expected safety concerns, standard Adverse Events (AEs) monitoring
will be implemented during the study
Additional endpoints:
1. Formula acceptability assessed by the Study Formula Satisfaction Questionnaire
2. Reported AEs and Serious Adverse Events (SAEs) including type, incidence, severity,
seriousness and relation to study formula consumption as well as concomitant medications
and non-pharmacological treatments.
- Select morbidities of interest (i.e., respiratory illnesses, GI illnesses, and
fever) will be collected as part of AE reporting and specific corresponding AE
guidance forms will be used to standardize reporting of such AEs
Trial design:
Uncontrolled, single arm, open-label, prospective study in infants (enrolled at postnatal age
7 days to 2 months) fed the study formula for 8 weeks (56 days)
A group of exclusively breastfed infants (BF) will serve as a reference group in parallel to
the study arm. For the BF group, Infants must have been exclusively consuming breast milk
since birth, and their parent(s) must have made the decision to continue exclusively
breastfeeding until at least 4 month of age
Trial population:
Healthy, male and female, term infants, 7 days postnatal age to 2 months of age at the
enrollment
Treatment duration:
Total study participation/intervention up to approximately 8 weeks
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05551975 -
Preterm Infants Fed a Human Milk Fortifier
|
N/A | |
Completed |
NCT01721512 -
The Growth and Development of Breast and Formula Fed Term Asian Infants
|
N/A | |
Completed |
NCT01162798 -
Preterm Infant Growth
|
N/A | |
Active, not recruiting |
NCT00970398 -
Effect of an Infant Formula on Infant Growth, Health and Immune Functions
|
N/A | |
Completed |
NCT01666457 -
Impact of Implementing an Infant Driven Feeding Program on Oral Feeding and Growth Outcomes of Medically Fragile Infants in the Neonatal ICU (NICU)
|
||
Completed |
NCT00808756 -
Study on Fermentable Carbohydrates in Healthy Infants
|
N/A | |
Completed |
NCT00997971 -
Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein
|
Phase 3 | |
Completed |
NCT03276663 -
Growth of Healthy Term Infants Fed a Partially Hydrolyzed Follow-up Formula
|
N/A | |
Recruiting |
NCT02695784 -
Probiotics After Discharge
|
Phase 4 | |
Withdrawn |
NCT02860026 -
Growth and Tolerance of Healthy Term Infants Fed Cow's Milk-Based Infant Formulas
|
N/A | |
Completed |
NCT01128517 -
Maternal Education on Complementary Feeding and Infant Outcome
|
N/A | |
Completed |
NCT00282113 -
Effects of Probiotic and Prebiotic Combinations on Premature Infants
|
N/A | |
Completed |
NCT03276884 -
Growth and Tolerance of Young Infants
|
N/A | |
Completed |
NCT05302427 -
Infant Massage and Infant Growth, Mother-Infant Attachment, and Maternal Self-Confidence
|
N/A | |
Not yet recruiting |
NCT05616117 -
Next-generation Effects of Vitamin D Supplementation in Pregnancy
|
||
Active, not recruiting |
NCT02410057 -
Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula
|
N/A | |
Completed |
NCT01158352 -
Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Innovative Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children
|
N/A | |
Completed |
NCT01210391 -
Growth of Infants Fed an Extensively Hydrolyzed Infant Formula
|
N/A | |
Completed |
NCT01109849 -
Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth
|
Phase 4 | |
Completed |
NCT00705445 -
Evaluation of Zinc and / or Micronutrient Supplementation on Intestinal Flora, Diarrheal Disease Burden, Intestinal Mucosal Integrity and Growth Among Children of Pakistan
|
Phase 2/Phase 3 |